Magnesium inhibits norepinephrine release by blocking N-type calcium channels at peripheral sympathetic nerve endings

Hypertension

Volumn 44, Issue 6, 2004, Pages 897-902

  Shimosawa, Tatsuo ^a   Takano, Koji ^a   Ando, Katsuyuki ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Catecholamines; Cocaine; Hypertension; Ion channels

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CATECHOLAMINE; HYDRALAZINE; MAGNESIUM; NERVE GROWTH FACTOR; NORADRENALIN; VASODILATOR AGENT; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CATECHOLAMINE RELEASE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTROSTIMULATION; FOLLOW UP; HYPOTENSION; MALE; MESENTERIC ARTERY; NERVE CELL; NERVE ENDING; NONHUMAN; NORADRENALIN RELEASE; PATCH CLAMP; PERIPHERAL NERVE; PRIORITY JOURNAL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; SYMPATHETIC NERVE; SYMPATHETIC TONE; TACHYCARDIA;

ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; ELECTRIC STIMULATION; HYDRALAZINE; MAGNESIUM CHLORIDE; MAGNESIUM SULFATE; NEURONS; NOREPINEPHRINE; PC12 CELLS; PERIPHERAL NERVES; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 9644295554     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000146536.68208.84     Document Type: Article

References (32)

1. Rude RK. Physiology of magnesium metabolism and the important role of magnesium in potassium deficiency. Am J Cardiol. 1989;63:31G-34G.
2. Touyz RM, Milne FJ. Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. Am J Hypertens. 1999;12:757-765.
3. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of Magnesium supplementation in hypertensive patients. Hypertension. 1998;32:260-265.
4. 2+ currents of capillary endothelial cells from rat brain. FEBS Lett. 1996;394:335-339.
5. 2+ in acutely isolated hippocampal CA1 pyramidal cells of the guinea-pig. Brain Res. 1996;728:204-208.
6. Murasato Y, Harada Y, Ikeda M, Nakashima Y, Hayashida Y. Effect of magnesium deficiency on autonomic circulatory regulation in conscious rats. Hypertension. 1999;34:247-252.
7. Altura BM, Altura BT, Gebrewold A, Ising H, Gunther T. Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science. 1984;223:1315-1317.
8. Frohlich ED, McLoughlin MJ, Losem CJ, Ketelhut R, Messerli FH. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 1991;68:1346-1350.
9. Zdanowicz MM, Barletta MA. Protective role of magnesium in catecholamine-induced arrhythmia and toxicity in vitro. Magnesium Research. 1991;4:153-162.
10. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290:2669-2676.
11. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
12. 2+ channels by nerve growth factor and the v-src oncogene in rat pheochromocytoma cells. J Physiol (Lond). 1993;465:325-342.
13. Greene L, Tischler A. PC 12 pheochromocytoma cultures in neurobiological research. Adv Cell Neurobiol. 1982;3:373-414.
14. Shimosawa T, Fujita T. Hypotensive effect of newly identified peptide, proadrenomedullin N-terminal 20 peptide. Hypertension. 1996;28:325-329.
15. 2-terminal 20 peptide, a new product of the adrenomedullin gene, inhibits norepinephrine overflow from nerve endings. J Clin Invest. 1995;96:1672-1676.
16. Pitts DK, Marwah J. Autonomic actions of cocaine. Can J Physiol Pharmacol. 1988;67:1168-1176.
17. Salt P. Inhibition of noradrenaline uptake in the isolated rat heart by steroids, clonidine and methoxylated phenylethylamines. Eur J Pharmacol 1979;20:329-340.
18. 2+ channel current through a pertussis toxin-sensitive G protein in rat pheochromocytoma-derived PC 12 cells. J Clin Invest. 1996;98:14-17.
19. Altura BM, Altura BT. Influence of magnesium on drug-induced contractions and ion content in rabbit aorta. Am J Physiol. 1971;220:938-944.
20. Turlapaty PDMV, Altura BM. Extracellular magnesium ions control calcium exchange and content of vascular smooth muscle. Eur J Pharmacol. 1978;52:421-423.
21. Fujita T, Ito Y, Ando K, Noda H, Ogata E. Attenuated vasodilator responses to Mg 2+ in young patients with borderline hypertension. Circulation. 1990;82:384-393,
22. 2+ channel by nerve growth factor. Brain Res. 1985;341:381-384.
23. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
24. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
25. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981-2997.
26. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
27. Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585-592.
28. Baxter GF, Sumeray MS, Walker JM. Infarct size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental studies. Lancet. 1996;348:1424-1426.
29. Mizushima S, Cappuccio FP, Nichols R, Elliott P. Dietary magnesium intake and blood pressure. J Hum Hypertens. 1998;12:447-453.
30. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K, Miho N. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999;33:1447-1452.
31. Yagi S, Goto S, Yamamoto T, Kurihara S, Katayama S. Effect of cilnidipine on insulin sensitivity in patients with essential hypertension. Hypertens Res. 2003;26:383-387.
32. Varagic J, Susic D, Frohlich ED. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens. 2002;20:317-322.